Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2021 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to...
July 19, 2021 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
June 21, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021

New analyses from the Phase 3 REGENERATE study highlight the relationship between early reductions of aminotransferases and fibrosis improvement in patients with fibrosis due to NASH treated with...
June 15, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the Raymond James 2021 Human Health Innovation Conference

NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
June 09, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer

NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
June 07, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Appoints Andrew Saik as Chief Financial Officer

NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
May 27, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the Jefferies Virtual Healthcare Conference

NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
May 26, 2021 16:30 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
May 12, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
May 06, 2021 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Worldwide Ocaliva® net sales of $81.7M, representing 12% growth over the prior year quarter Company narrows 2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 million...